Literature DB >> 28448680

22q11.2 deletion syndrome lowers seizure threshold in adult patients without epilepsy.

Robert G Wither1, Felippe Borlot1,2,3, Alex MacDonald4, Nancy J Butcher4,5, Eva W C Chow4,6, Anne S Bassett4,5,6,7,8,9, Danielle M Andrade1,3.   

Abstract

OBJECTIVE: Previous studies examining seizures in patients with 22q11.2 deletion syndrome (22q11.2DS) have focused primarily on children and adolescents. In this study we investigated the prevalence and characteristics of seizures and epilepsy in an adult 22q11.2DS population.
METHODS: The medical records of 202 adult patients with 22q11.2DS were retrospectively reviewed for documentation of seizures, electroencephalography (EEG) reports, and magnetic resonance imaging (MRI) findings. Epilepsy status was assigned in accordance with 2010 International League Against Epilepsy Classification.
RESULTS: Of 202 patients, 32 (15.8%) had a documented history of seizure. Of these 32, 23 (71.8%) had acute symptomatic seizures, usually associated with hypocalcemia and/or antipsychotic or antidepressant use. Nine patients (9/32, 28%; 9/202, 4%) met diagnostic criteria for epilepsy. Two patients had genetic generalized epilepsy; two patients had focal seizures of unknown etiology; two had epilepsy due to malformations of cortical development; in two the epilepsy was due to acquired structural changes; and in one patient the epilepsy could not be further classified. SIGNIFICANCE: Similarly to children, the prevalence of epilepsy and acute symptomatic seizures in adults with 22q11.2DS is higher than in the general population. Hypocalcemia continues to be a risk factor for adults, but differently from kids, the main cause of seizures in adults with 22q11.2DS is exposure to antipsychotics and antidepressants. Further prospective studies are warranted to investigate how 22q11.2 microdeletion leads to an overall decreased seizure threshold. Wiley Periodicals, Inc.
© 2017 International League Against Epilepsy.

Entities:  

Keywords:  Acute symptomatic seizure; Clozapine; Electroencephalography; Genetics; Prevalence studies; Provoked seizures; Seizure semiology

Mesh:

Year:  2017        PMID: 28448680     DOI: 10.1111/epi.13748

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

Review 2.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

3.  Prevalence of Pathogenic Copy Number Variation in Adults With Pediatric-Onset Epilepsy and Intellectual Disability.

Authors:  Felippe Borlot; Brigid M Regan; Anne S Bassett; D James Stavropoulos; Danielle M Andrade
Journal:  JAMA Neurol       Date:  2017-11-01       Impact factor: 18.302

Review 4.  22q11.2 Deletion Syndrome-Associated Parkinson's Disease.

Authors:  Erik Boot; Anne S Bassett; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2018-11-09

5.  Epilepsy and seizures in young people with 22q11.2 deletion syndrome: Prevalence and links with other neurodevelopmental disorders.

Authors:  Christopher B Eaton; Rhys H Thomas; Khalid Hamandi; Gareth C Payne; Michael P Kerr; David E J Linden; Michael J Owen; Adam C Cunningham; Ullrich Bartsch; Siske S Struik; Marianne B M van den Bree
Journal:  Epilepsia       Date:  2019-04-11       Impact factor: 5.864

6.  Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review.

Authors:  Janna de Boer; Erik Boot; Lissa van Gils; Therese van Amelsvoort; Janneke Zinkstok
Journal:  Am J Med Genet A       Date:  2019-08-13       Impact factor: 2.802

7.  Treatment of Epilepsy Associated with Common Chromosomal Developmental Diseases.

Authors:  Magdalena Budisteanu; Claudia Jurca; Sorina Mihaela Papuc; Ina Focsa; Dan Riga; Sorin Riga; Alexandru Jurca; Aurora Arghir
Journal:  Open Life Sci       Date:  2020-02-28       Impact factor: 0.938

Review 8.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

9.  Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2.

Authors:  Erik Boot; Nancy J Butcher; Sean Udow; Connie Marras; Kin Y Mok; Satoshi Kaneko; Matthew J Barrett; Paolo Prontera; Brian D Berman; Mario Masellis; Boris Dufournet; Karine Nguyen; Perrine Charles; Eugénie Mutez; Teodor Danaila; Aurélia Jacquette; Olivier Colin; Sophie Drapier; Michel Borg; Ania M Fiksinski; Elfi Vergaelen; Ann Swillen; Annick Vogels; Annika Plate; Claudia Perandones; Thomas Gasser; Kristien Clerinx; Frédéric Bourdain; Kelly Mills; Nigel M Williams; Nicholas W Wood; Jan Booij; Anthony E Lang; Anne S Bassett
Journal:  Neurology       Date:  2018-05-11       Impact factor: 9.910

10.  Periventricular nodular heterotopia in 22q11.2 deletion and frontal lobe migration.

Authors:  Arezoo Rezazadeh; Eduard Bercovici; Tim-Rasmus Kiehl; Eva W Chow; Timo Krings; Anne S Bassett; Danielle M Andrade
Journal:  Ann Clin Transl Neurol       Date:  2018-09-23       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.